Although colorectal cancer (CRC) screening has reduced the incidence of and mortality from
CRC, chemoprevention strategies have the potential to further reduce CRC incidence and …

Growing evidence showed the increased prevalence of cancer incidents, particularly
colorectal cancer, among type 2 diabetic mellitus patients. Antidiabetic medications such as …

The strategy of using existing drugs originally developed for one disease to treat other
indications has found success across medical fields. Such drug repurposing promises faster …

Purpose Metformin may have a role in reducing the incidence of colorectal cancer (CRC)
and improving survival outcome. This meta-analysis explored the effect of metformin use on …

Aim We carried out this meta-analysis on all published studies to estimate the overall cancer
risk of the use of metformin in T2DM patients. Methods We searched the PubMed, Embase …

Colorectal cancer (CRC) is the most common malignancy-related cause of death worldwide.
The prognosis of CRC patients is strongly correlated with elevated plasma copper. The …

Metformin (MTF) is a natural compound derived from the legume Galega officinalis. It is the
first line antidiabetic drug for type 2 diabetes (T2D) treatment. One of its main antidiabetic …

Colorectal cancer (CRC) is a malignancy in the gastro-intestinal (GI) tract which has very
limited treatment options still, despite the vast amount of research undertaken. CRC was first …

Metformin has been used for a long time as an antidiabetic medication for type 2 diabetes. It
is used either as a monotherapy or in combination with other antidiabetic medications. The …

Background The biguanide drug metformin is a safe and widely prescribed drug for type 2
diabetes. Interestingly, hundreds of clinical trials have been set to evaluate the potential role …